Reference Intervals With Indirect Methods in Italy
REFIND-IT
1 other identifier
observational
1,000,000
1 country
24
Brief Summary
Reference intervals are an essential tool for the clinical interpretation of laboratory test results. Traditionally, these interval are determined using samples from healthy individuals, a process that is resource-intensive, time-consuming, and require the active recruitment of healthy volunteers. In recent years, due to the increasing availability of electronic health record (EHR) databases and the growing number of laboratory tests, it is possible to determine the reference intervals indirectly. This approach relies on the analysis of routine data acquired in clinical laboratories, eliminating the need for active recruiting healthy subjects and significantly reducing costs. Moreover, the method has the potential to eliminate the selection bias of an ultra-healthy population typical of the direct methods. The indirect methods for determining reference intervals have evolved from simple strategies of isolating the healthy population using sample metadata, to sophisticated statistical models that effectively distinguish normal from pathological distributions. One of the advanced techniques, RefineR, has reached an excellent combination of accuracy, robustness, and computational efficiency, outperforming previous methods. It has been implemented as an open-source R package, facilitating its application in real-world settings. In recognition of these advantages, the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine), through its Committee on Reference Intervals and Decision Limits (C-RIDL), has promoted the adoption of indirect methods for determining reference intervals, highlighting the advantages of this strategy, including greater speed, lower costs, and the absence of a need to recruit healthy donors. Furthermore, a recent study has highlighted age-related physiological variations in hemoglobin levels in elderly population. This underscores the need for defining age-specific reference intervals which are currently absent from most laboratory reports, potentially impacting diagnostic accuracy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2025
Typical duration for all trials
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 8, 2025
CompletedFirst Submitted
Initial submission to the registry
February 19, 2026
CompletedFirst Posted
Study publicly available on registry
February 25, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2028
February 25, 2026
February 1, 2026
2.6 years
February 19, 2026
February 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Define indirect reference intervals for complete blood count (CBC) parameters by analyzing large-scale retrospective routine laboratory data.
up to 3 years
Secondary Outcomes (3)
Assess regional differences by comparing results across 10 Italian regions.
up to 3 years
Establish age- and sex-specific reference intervals
up to 3 years
Evaluate inter-instrument variations by considering results obtained from different analytical platforms.
up to 3 years
Eligibility Criteria
The study population consists of all patients undergoing routine laboratory testing during the year 2024 at the participating centers.
You may qualify if:
- no one
You may not qualify if:
- no one
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (24)
ASL Bari, Ospedale della Murgia, Altamura
Altamura, Altamura, Italy
Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona
Ancona, Ancona, Italy
Azienda USL Toscana Sud Est, Arezzo
Arezzo, Arezzo, Italy
Azienda ULSS 1 Dolomiti
Belluno, Belluno, Italy
Azienda Ospedaliero-Universitaria Careggi, Firenze
Florence, Firenze, Italy
IRCCS Istituto Clinico Humanitas, Milano
Milan, Milano, Italy
IRCCS Ospedale San Raffaele, Milano
Milan, Milano, Italy
Azienda Ospedaliero-Universitaria di Modena
Modena, Modena, Italy
Bianalisi Carate Brianza, Monza e Brianza
Monza, Monza, Italy
Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
Novara, Novara, Italy
Azienda Ospedale Università Padova
Padua, Padova, Italy
Azienda Ospedaliera Universitaria Policlinico 'Paolo Giaccone' di Palermo
Palermo, Palermo, Italy
Centro di Riferimento Oncolgico -IRCCS
Aviano, Pordenone, 33081, Italy
Azienda Sanitaria Friuli Occidentale, Ospedale di Pordenone
Pordenone, Pordenone, Italy
Azienda Ospedaliera Universitaria Senese,
Siena, Siena, Italy
Azienda Sanitaria Universitaria Giuliano Isontina
Trieste, Trieste, Italy
Azienda Sanitaria Universitaria Friuli Centrale, Ospedale di Udine
Udine, Udine, Italy
AULSS 3 Serenissima, Ospedale di Mestre
Mestre, Venezia, Italy
Azienda Ospedaliera Universitaria Integrata di Verona
Verona, Verona, Italy
AULSS 8 Berica, Ospedale S. Bortolo di Vicenza
Vicenza, Vicenza, Italy
Ospedale di Desio, ASST Brianza
Desio, Italy
ASL5 Spezzino, La Spezia
La Spezia, Italy
ASST Grande Ospedale Metropolitano Niguarda, Milano
Milan, Italy
Azienda ULSS 2 Marca Trevigiana
Treviso, Italy
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 19, 2026
First Posted
February 25, 2026
Study Start
October 8, 2025
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
June 1, 2028
Last Updated
February 25, 2026
Record last verified: 2026-02